Skip to main content
. 2019 Jan 28;5(2):277–289. doi: 10.1021/acscentsci.8b00688

Figure 6.

Figure 6

Treatment with F-DMA/CCL19-induced maturation of DCs. When CT26 cells were transfected with GS, F-DMA, F-DMA/pVax, DMA/CCL19, and F-DMA/CCL19 for 72 h, the supernatants from different treatments were added to DCs and treated for 24 h. The subsets of MHC-II+ (A) and CD86+ (B) DCs were tested by flow cytometry (mean ± SEM, n = 3; *, p < 0.05, **, p < 0.01; F-DMA/CCL19 versus DMA/CCL19; F-DMA/CCL19, DMA/CCL19 versus GS, DMA, DMA/pVax). The results represent three independent experiments.